Loading…
Ironwood Pharmaceuticals, Inc. is projected to rise to $5.19 by 2027, a +16% move from its current price of $4.47. IRWD is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $4.32 | $4.47 | $4.62 | +0.01% |
| Jul 14 | $4.26 | $4.47 | $4.69 | +0.01% |
| Jul 15 | $4.22 | $4.47 | $4.74 | +0.02% |
| Jul 16 | $4.18 | $4.47 | $4.78 | +0.03% |
| Jul 17 | $4.15 | $4.47 | $4.82 | +0.04% |
| Jul 18 | $4.12 | $4.47 | $4.86 | +0.04% |
| Jul 19 | $4.09 | $4.47 | $4.89 | +0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.09 | $4.47 | $4.89 | +0.05% |
| Week 2 | $3.94 | $4.47 | $5.08 | +0.10% |
| Week 3 | $3.84 | $4.48 | $5.22 | +0.16% |
| Week 4 | $3.75 | $4.48 | $5.35 | +0.21% |
| Week 5 | $3.67 | $4.48 | $5.47 | +0.26% |
| Week 6 | $3.60 | $4.48 | $5.58 | +0.31% |
| Week 7 | $3.54 | $4.49 | $5.68 | +0.37% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ironwood Pharmaceuticals, Inc. is a biotechnology company focused on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.
The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Ironwood Pharmaceuticals, Inc. (IRWD) is currently priced at $4.77 per share and has a market capitalization of $785.21M, ranking 2725 by market cap.
The overall price outlook is positive, with a year-by-year forecast showing upside potential driven by rising average prices into the latter years. The forecast projects an average price of $10.53 by 2030 and a peak average of $58.51 by 2050, with a maximum of $118.35 in 2050. Implied returns rise to 120.7% by 2030 and to 1126.6% by 2050, suggesting meaningful long-term upside while acknowledging the inherent uncertainty of forecasts.
A major floor 41.8% below — a decisive break under it would weaken the trend.
The nearest floor, 28.0% below — buyers have tended to step in here.
The nearest ceiling, 6.7% above — a clean break opens room to run.
A major ceiling 27.6% above — clearing it would confirm fresh momentum.
Key IRWD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IRWD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.55 | Sell | $4.51 | Sell |
| MA 10 | $4.38 | Buy | $4.37 | Buy |
| MA 20 | $4.05 | Buy | $4.15 | Buy |
| MA 50 | $3.91 | Buy | $3.95 | Buy |
| MA 100 | $3.81 | Buy | $3.81 | Buy |
| MA 200 | $3.47 | Buy | $3.49 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.62 | Neutral |
| Stoch RSI (14) | 33.68 | Neutral |
| CCI (20) | 83.51 | Neutral |
| Williams %R (14) | -31.58 | Info |
| MACD (12,26,9) | 0.07 | Buy |
| ROC (12) | 15.80 | Buy |
| Bollinger %B (20,2) | 0.78 | Neutral |
| Stochastic %K (14) | 68.42 | Neutral |
| TRIX (15) | 0.62 | Buy |
| Awesome (5,34) | 0.73 | Buy |
| Ultimate (7,14,28) | 65.60 | Neutral |
| Momentum (10) | 0.63 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 4.73 | Sell |
| ADX (14) | 22.96 | Buy |
| ATR (14) | 0.13 | Info |
The 30-day technical picture is bullish, with RSI14 at 70 indicating strong momentum. The price is above both the SMA50 and SMA200, which sit at $3.89 and $3.44 respectively. Near-term support is at $3.22 and resistance at $4.77, framing a 30-day range of $3.81 to $5.98.
The stock’s 30-day range and directional indicators align with a constructive setup, and the current price of $4.77 sits within this range. Market volatility is elevated, with an annualized volatility of 70%, reinforcing the need for risk-aware positioning.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.04 | $4.47 | $5.42 | 0% | Neutral | |
| $4.04 | $5.19 | $7.10 | +16% | Neutral | |
| $4.40 | $5.85 | $8.36 | +31% | Bullish | |
| $5.72 | $7.84 | $11.61 | +75% | Bullish | |
| $6.68 | $9.40 | $14.31 | +110% | Bullish | |
| $6.55 | $9.43 | $14.73 | +111% | Bullish | |
| $7.38 | $10.87 | $17.36 | +143% | Bullish | |
| $7.53 | $11.33 | $18.46 | +153% | Bullish | |
| $7.38 | $11.34 | $18.82 | +154% | Bullish | |
| $9.80 | $15.34 | $25.91 | +243% | Bullish | |
| $12.48 | $21.36 | $38.74 | +378% | Bullish | |
| $24.33 | $48.83 | $98.13 | +992% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.04 | $4.47 | $5.28 | +0.00% |
| August 2026 | $3.69 | $4.38 | $5.36 | -2.03% |
| September 2026 | $3.76 | $4.50 | $5.58 | +2.77% |
| October 2026 | $3.67 | $4.43 | $5.56 | -1.56% |
| November 2026 | $3.47 | $4.22 | $5.34 | -4.81% |
| December 2026 | $3.47 | $4.24 | $5.42 | +0.51% |
Click any year to see its month-by-month IRWD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, IRWD could reach as high as $5.42, with a base case around $4.47 and support toward $3.04 — roughly 0% from $4.47. A consolidation phase looks the most probable path here.
Expect IRWD to range from $4.04 to $7.10 through 2027. The $5.19 average target implies a +16% move from current prices. That is up +16% on the projected 2026 average. Price action looks broadly range-bound.
The IRWD price prediction for 2028 points to an average of $5.85 (low $4.40, high $8.36) — a potential gain of +31% on today's $4.47. Buyers look set to stay in control over this stretch.
In 2029, IRWD is projected to trade between $5.72 and $11.61, averaging $7.84 — a potential gain of +75% from today's $4.47. That is up +34% on the projected 2028 average. Momentum favours further upside here.
Ironwood Pharmaceuticals, Inc.'s 2030 outlook centres on $9.40, within a $6.68 to $14.31 range. That is up +20% on the projected 2029 average. That marks a +110% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, IRWD could reach as high as $14.73, with a base case around $9.43 and support toward $6.55 — roughly +111% from $4.47. Momentum favours further upside here.
Expect IRWD to range from $7.38 to $17.36 through 2032. The $10.87 average target implies a +143% move from current prices. That is up +15% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The IRWD price prediction for 2033 points to an average of $11.33 (low $7.53, high $18.46) — a potential gain of +153% on today's $4.47. Momentum favours further upside here.
In 2034, IRWD is projected to trade between $7.38 and $18.82, averaging $11.34 — a potential gain of +154% from today's $4.47. That is up 0% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Ironwood Pharmaceuticals, Inc.'s 2035 outlook centres on $15.34, within a $9.80 to $25.91 range. That is up +35% on the projected 2034 average. That marks a +243% change versus current levels. Momentum favours further upside here.
By 2040, IRWD could reach as high as $38.74, with a base case around $21.36 and support toward $12.48 — roughly +378% from $4.47. Buyers look set to stay in control over this stretch.
Expect IRWD to range from $24.33 to $98.13 through 2050. The $48.83 average target implies a +992% move from current prices. That is up +129% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in IRWD today (≈ 223.713647 IRWD) could be worth
$10,923.9
+$9,923.9 (+992%) by 2050 · US Dollar
Based on the average projected IRWD price of $48.83 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IRWDwould be worth at today's price.
$1,000 invested in IRWD on Jul 10, 2025 (≈ 1,282.051329 IRWD) would be worth
$5,730.77
+$4,730.77 (+473.1%) today · 5.73× · US Dollar
Based on a IRWD entry price of $0.78 vs. today's $4.47.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.33 | $1,032.33 | +3.2% |
| 1 month ago | $3.35 | $1,334.33 | +33.4% |
| 3 months ago | $3.63 | $1,231.4 | +23.1% |
| 6 months ago | $4.47 | $1,000 | +0.0% |
| 1 year ago | $0.78 | $5,730.77 | +473.1% |
| All time (5.0y) ago | $12.38 | $361.07 | -63.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IRWD forecast.
Our base-case forecast reaches $8.90 around 2030.
Implied market cap at $8.90: $1.47B
The multi-year forecast shows a bullish trajectory from 2027 onward, with the average price climbing from $5.64 in 2027 to $58.51 by 2050. Notable intermediate milestones include 2030 avg $10.53 and 2035 avg $18.00, illustrating continued upside as sentiment remains bullish in the forecast horizon. By 2030 the forecasted average price is $10.53 and ROI is projected at 120.7%.
In 2040 the average price rises to $25.10 with a projected ROI of 426.3%, and by 2050 the average price reaches $58.51 with a projected ROI of 1126.6%.
The range of possible outcomes widens over time, with 2030 min $7.46 and max $16.09, 2040 min $14.55 and max $45.78, and 2050 min $28.81 and max $118.35, reflecting ongoing upside potential and greater uncertainty at longer horizons. Throughout much of the horizon the sentiment is bullish, signaling sustained optimistic expectations for IRWD, while also underscoring that these are estimates, not guarantees.
Tap a question to reveal the answer.
2030 forecast: avg $10.53, min $7.46, max $16.09, ROI 120.7%, sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward, with avg price rising to $58.51 by 2050 and ROI reaching 1126.6%. However, these are estimates, not guarantees.
2035 is forecast to have an avg price of $18.00 and 2040 to have an avg price of $25.10, indicating that the price could surpass $20 by 2040.
Ironwood markets linaclotide for irritable bowel syndrome with constipation or chronic idiopathic constipation in adults and functional constipation in pediatric patients under LINZESS and CONSTELLA. It is developing IW-3300 for visceral pain conditions and Apraglutide for short bowel syndrome and acute graft versus host disease; it also has partnerships with AbbVie, AstraZeneca, and Astellas for linaclotide development and commercialization.
Ironwood Pharmaceuticals, Inc. Community Discussion
0Share your Ironwood Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.